Drugs / Ergoferon
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 33 trials · 3 met primary | ||||||
| Phase 3 | NCT05069649 | Oct 2021 → Apr 2022 | — | Materia Medica Holding | Completed | Met primary |
| Phase 3 | NCT01843842 | Apr 2013 → Mar 2015 | respiratory tract infectious disorder | Materia Medica Holding | Completed | Met primary |
| Phase 3 | NCT01765920 | Dec 2012 → Dec 2014 | respiratory tract infectious disorder | Materia Medica Holding | Completed | Met primary |
| Phase 44 trials · 3 met primary | ||||||
| Phase 4 | NCT03039621 | Oct 2016 → Jan 2019 | viral respiratory tract infection | Materia Medica Holding | Completed | Met primary |
| Phase 4 | NCT03039699 | Jun 2016 → Jun 2019 | intestinal infectious disease | Materia Medica Holding | Completed | Met primary |
| Phase 4 | NCT01850446 | Feb 2015 → Apr 2018 | influenza | Materia Medica Holding | Completed | Met primary |
| Phase 4 | NCT01804946 | Feb 2011 → Apr 2014 | influenza | Materia Medica Holding | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ergoferon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01843842 ↗ |
| Modality | Protein / enzyme biologic | “Ergoferon is an antiviral complex drug containing released-active forms of antibodies to interferon gamma, CD4, and histamine.” PMID 27616034 ↗ Sep 2016 |
| Route | Oral | “Oral use.” NCT01765920 ↗ |
| Target | CD4 | “Ergoferon is an antiviral complex drug containing released-active forms of antibodies to interferon gamma, CD4, and histamine.” PMID 27616034 ↗ Sep 2016 |